New Milestone In Psychedelics Market: Canadian Start-Up Will Export Psilocybin And MDMA To Australia
Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now!
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to…
Psyched: DEA’s Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
COMPASS’ Securities Purchase Agreement Is Big News
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the…
Filament Health’s Q1 2023 Financial Results, Material Uncertainty On The Horizon
Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023.
Cybin Reports Q3 Earnings, Says Psilocybin Tial Is Progressing As MDD Treatment
Cybin Inc. (NYSE: CYBN) has shared its unaudited financial results for the third quarter that ended Dec. 31, 2022.
The company held total cash of $16.9 (CA$22.5) million as of Dec. 31, 2022, and $15 million as of Feb. 14, 2023.
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”
Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS’ Published Results
(Part two of a four-part series)
See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes
(Part one of a four-part series)